Multiple myeloma
We are striving to change outcomes for every patient with multiple myeloma, at every stage of disease, by applying cutting-edge technologies to reshape care – towards our ultimate goal of delivering a cure.
Our legacy of delivering firsts is a testament to our ambition to get in front of multiple myeloma and we remain focused on continuing to disrupt in areas of high unmet medical need to transform care and deliver curative regimens.
We want to get in front of multiple myeloma and give people a chance to live longer, better lives free of their disease so they can focus on what’s important to them.
A multiple myeloma diagnosis is unique to each individual, which means we need more than just one option to face this complex disease. One simple breakthrough treatment isn’t enough when every patient is unique. That’s why we’re pursuing a portfolio of immunotherapies that target the disease from every angle, and at every stage. Curing multiple myeloma is our mission; we are prepared, and we are leading the way.”
With our commitment and expertise, we are confident in our ability to continue to deliver tailored treatment options for all patients with multiple myeloma, and ultimately we hope to enable physicians to treat to cure.
References
[1] Multiple Myeloma Research Foundation. Understanding Multiple Myeloma. Available at:
https://themmrf.org/multiple-myeloma/ Last accessed: March 2024. We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
[2] Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347.
[3] Hernández-Rivas JÁ, et al. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1-23.
[4] Podar K, Leleu X. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers (Basel). 2021;13(20):5154.
[5] ECIS - European Cancer Information System. Estimates of cancer incidence and mortality in 2022, by country. Multiple myeloma. Available at:
https://ecis.jrc.ec.europa.eu/explorer.php. Last accessed: March 2024.
[6] Dhanasiri S, et al. Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study. Clin Ther. 2021;43(11):1983-1996.e3.
[7] Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430.
[8] American Cancer Society. Multiple myeloma: causes, risk factors, and prevention. Available at:
https://www.cancer.org/content/dam/CRC/PDF/Public/8739.00.pdf
You are now leaving J&J Innovative Medicine EMEA
[9] Velcade summary of product characteristics. Available at:
https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf. Last accessed: March 2024.
[10] The Multiple Myeloma Call-To-Action. Available at:
https://www.mmcalltoaction.com/pdf/MMDifference.pdf. Last accessed: March 2024.
[11] Health and Environment Alliance (HEAL). Prostate cancer. Available at:
https://www.env-health.org/IMG/pdf/prostate_testical.pdf. Last accessed: March 2024.
[12] Kamaneh Montazeri & Joaquim Bellmunt. Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology. 2020;13(1):1-6.
[13] Cancer.Net. Lung Cancer - Non-Small Cell: Statistics. Available at:
https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Last accessed: March 2024.
CP-459038
September 2024